Scarlet Therapeutics is developing a unique platform that makes modified therapeutic red blood cells to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could be used more broadly to target cancer and autoimmune diseases. Modified red blood cells have many unique qualities, including pervasive reach throughout the body, a long active life and the ability to carry therapeutic proteins.